The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...

Investing.com -- Hims & Hers Health (NYSE: HIMS) stock rose 2% on Wednesday after the digital health platform announced plans to expand into Canada in 2026, coinciding with the anticipated first ...

Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk's patent on its branded drugs Ozempic and Wegovy is set to expire in January. "Canada is a major ...

Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...